KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Assets (2018 - 2025)

Historic Current Assets for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $360.5 million.

  • Esperion Therapeutics' Current Assets rose 1720.31% to $360.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year increase of 1720.31%. This contributed to the annual value of $338.0 million for FY2024, which is 6810.38% up from last year.
  • Esperion Therapeutics' Current Assets amounted to $360.5 million in Q3 2025, which was up 1720.31% from $342.6 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Current Assets peaked at $365.6 million during Q1 2024, and registered a low of $170.7 million during Q3 2021.
  • Its 5-year average for Current Assets is $283.1 million, with a median of $275.2 million in 2021.
  • Per our database at Business Quant, Esperion Therapeutics' Current Assets crashed by 2970.93% in 2021 and then surged by 6810.38% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Current Assets (Quarter) stood at $329.0 million in 2021, then fell by 25.01% to $246.7 million in 2022, then decreased by 18.49% to $201.1 million in 2023, then skyrocketed by 68.1% to $338.0 million in 2024, then increased by 6.65% to $360.5 million in 2025.
  • Its Current Assets stands at $360.5 million for Q3 2025, versus $342.6 million for Q2 2025 and $318.8 million for Q1 2025.